Pharmazz has several novel drug products in various clinical stages that are first-in-class with unique mechanisms of action that are different from those of existing therapies. The company plans to commercialize the potential of drug products that boost endogenous repair mechanisms in the (1) brain to treat diseases such as stroke, Alzheimer’s disease, spinal cord injury, amyotrophic lateral sclerosis, and other neurodegenerative disorders, (2) circulatory system to treat shock and circulatory failure, and potentially cardiac arrest. In addition, products are being developed to manage postoperative pain and diabetic ketoacidosis.

Pharmazz possesses a world-class team that is highly focused in its efforts to first commercialize drug products for hypovolemic shock, cerebral ischemic stroke, and Alzheimer’s disease. The preclinical and clinical results of the drug products for these indications are highly promising, and provide an excellent opportunity to bring first-in-class pharmaceuticals to the market. Patents have been granted in the USA, Europe, China, Canada, Australia, India, and other countries.